TransCode Therapeutics Inc (NASDAQ:RNAZ) has a beta value of 1.02 and has seen 0.11 million shares traded in the last trading session. The company, currently valued at $7.25M, closed the last trade at $10.36 per share which meant it lost -$0.3 on the day or -2.81% during that session. The RNAZ stock price is -540.25% off its 52-week high price of $66.33 and 74.32% above the 52-week low of $2.66. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.22 million shares traded. The 3-month trading volume is 1.65 million shares.
TransCode Therapeutics Inc (NASDAQ:RNAZ) trade information
Sporting -2.81% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the RNAZ stock price touched $10.36 or saw a rise of 18.87%. Year-to-date, TransCode Therapeutics Inc shares have moved 207.42%, while the 5-day performance has seen it change 5.07%. Over the past 30 days, the shares of TransCode Therapeutics Inc (NASDAQ:RNAZ) have changed 224.76%. Short interest in the company has seen 0.37 million shares shorted with days to cover at 0.12.
TransCode Therapeutics Inc (RNAZ) estimates and forecasts
Figures show that TransCode Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have gained 37.75% over the past 6 months, with this year growth rate of 99.86%, compared to 17.50% for the industry.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -28.81% over the past 5 years. Earnings growth for 2025 is a modest 95.41% while over the next 5 years, the company’s earnings are expected to increase by 78.85%.
RNAZ Dividends
TransCode Therapeutics Inc is expected to release its next earnings report in March this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
TransCode Therapeutics Inc (NASDAQ:RNAZ)’s Major holders
Insiders own 7.78% of the company shares, while shares held by institutions stand at 21.41% with a share float percentage of 23.22%. Investors are also buoyed by the number of investors in a company, with TransCode Therapeutics Inc having a total of 10.0 institutions that hold shares in the company.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Extended Market Index Fund and Fidelity Total Market Index Fund. As of Nov 30, 2024 , the former fund manager holds about 0.41% shares in the company for having 2.89 shares of worth $29909.0 while later fund manager owns 1.18 shares of worth $12224.0 as of Nov 30, 2024 , which makes it owner of about 0.17% of company’s outstanding stock.
